AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7602342
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2 (arm A)
Trial: 7602342
Drug: Ifosfamide 5
RxNorm normalized name: ifosfamide 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide 5 g/m2 plus doxorubicin 50 mg/m2 (arm C)
Trial: 345561
Drug: Steroids (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (control group)
Trial: 25751578
Drug: Losmapimod, 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod, 7.5 mg bid orally
Trial: 17452162
Drug: Amiodarone (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (n = 696) at doses >2.0 mg/kg
Trial: 17452162
Drug: Amiodarone (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (n = 559) at doses >3.0 mg/kg
Trial: 17452162
Drug: Amiodarone (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (n = 219) at doses >4.0 mg/kg
Trial: 17452162
Drug: Amiodarone (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (n = 837) with a mean daily dose of 3.7 mg/kg (300 mg)
Trial: 14620524
Drug: New paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New paracetamol formulation with sodium bicarbonate
Trial: 14620524
Drug: Conventional paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional paracetamol formulation
Trial: 10632650
Drug: Bismuth-based quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based quadruple therapy (two single triple capsules containing 60 mg of bismuth subcitrate, 125 mg of tetracycline, and 125 mg of metronidazole) plus lansoprazole 30 mg b.d. for 7 days
Trial: 8938547
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (single subcutaneous dose)
Trial: 3868934
Drug: 4'-epi-adriamycin (EPI)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4'-epi-adriamycin (EPI) 50 mg/day for 6 days (regimen A)
Trial: 3868934
Drug: 4'-epi-adriamycin (EPI)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4'-epi-adriamycin (EPI) 60 mg/day for 3 days X 2 courses with 4 days interval (regimen B)
Trial: 20591171
Drug: Telerehabilitation (TR)
RxNorm normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation (TR) intervention using a combination of three videotaped visits and five telephone calls, an in-home messaging device, and additional telephonic contact as needed over a 3-month study period
Trial: 10337455
Drug: Myrtol standardized
RxNorm normalized name: myrtol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrtol standardized (MYS, Gelomyrtol forte, 3 x 300 mg)
Trial: 1819779
Drug: Intramuscular beta-interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular beta-interferon (3 x 10(6) IU for 10 consecutive days)
Trial: 1819779
Drug: Placebo intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intramuscular injections
Trial: 7146040
Drug: Controlled-release preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release preparation of ferrous glycine sulphate ('Ferrocontin' Continus)
Trial: 17470864
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg IV every 2 weeks and erlotinib 150 mg orally daily
Trial: 15370671
Drug: Early discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early discontinuation of antibiotic therapy in FUO patients
Trial: 3221960
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) for 6 weeks
Trial: 3221960
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with 60Co teletherapy in doses of 60 Gy (30 fr) for 6 weeks + CCNU in one dose of 100 mg/m repeated at intervals of 6‐8 weeks
Trial: 24565129
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (Group IVM)
Trial: 24565129
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (Group EM)
Trial: 24565129
Drug: Epidural morphine-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine-bupivacaine (Group EMB)
Trial: 24565129
Drug: Epidural morphine-ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine-ropivacaine (Group EMR)
Trial: 9624783
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin 500 mg once daily for 7 days
Trial: 9624783
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 500 mg twice daily for 10 days
Trial: 7837834
Drug: Zemide 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zemide 20 (30.4 mg tamoxifen dihydrogencitrate corresponding to 20 mg tamoxifen)
Trial: 7837834
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available tablet formulation (30.4 mg tamoxifen dihydrogencitrate corresponding to 20 mg tamoxifen)
Trial: 26814847
Drug: TwHF based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF based therapy in predictor positive (P+) group
Trial: 26814847
Drug: TwHF based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF based therapy in predictor negative (P-) group
Trial: 26814847
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and Sulfasalazine combination therapy (M) in predictor positive (P+) group
Trial: 26814847
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and Sulfasalazine combination therapy (M) in predictor negative (P-) group
Trial: 16978844
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus probiotic food (250 mL of yogurt containing Bifidobacterium animalis and Lactobacillus casei at 10^7 CFU/mL) for 1 week and administered for 3 months
Trial: 15343566
Drug: Balloon angioplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon angioplasty plus cilostazol (200 mg/day for 6 months)
Trial: 10937764
Drug: Iohexol (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol (350 mg I/ml)
Trial: 26314432
Drug: Arsenous acid
RxNorm normalized name: Arsenous acid
DrugBank: Arsenous acid (DB04456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arsenous acid (H3AsO3) treatment
Trial: 21391828
Drug: Peer health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer health workers (PHWs) providing care; specific dosage and duration not mentioned.
Trial: 12912807
Drug: Antioxidant vitamins
RxNorm normalized name: antioxidant vitamins with minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant vitamins C (500 mg/d) and E (400 IU/d) for 6 weeks
Trial: 1997932
Drug: MTC +
RxNorm normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTC + L (metoclopramide 1 mg/kg or 0.5 mg/kg + lorazepam 2.5 mg) in HE and ME regimens respectively
Trial: 1997932
Drug: ALZ +
RxNorm normalized name: Alzheimer's Disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALZ + L (alizapride 3 mg/kg or 1.5 mg/kg + lorazepam 2.5 mg) in HE and ME regimens respectively
Trial: 1997932
Drug: MTC +
RxNorm normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTC + L
Trial: 1997932
Drug: ALZ +
RxNorm normalized name: Alzheimer's Disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALZ + L
Trial: 31404221
Drug: Open abdomen
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open abdomen management with negative-peritoneal-pressure therapy (NPPT)
Trial: 30153752
Drug: Ketamine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine plus placebo (0.5 mg/kg of ketamine)
Trial: 30153752
Drug: Ketamine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine plus naltrexone (50 mg of naltrexone preceding ketamine)
Trial: 23158714
Drug: Univent blocker
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Capsule [Univer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Univent blocker (UNI)
Trial: 23158714
Drug: Coopdech bronchial
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coopdech bronchial blocker (BB)
Trial: 15353973
Drug: Low-dose Vacc-4x
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Vacc-4x
Trial: 15353973
Drug: High-dose Vacc-4x
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Vacc-4x
Trial: 27940188
Drug: Opioid agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid agonist treatment-as-usual
Trial: 25370889
Drug: Armodafinil 150
RxNorm normalized name: armodafinil 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil 150 mg daily for 56 days
Trial: 25370889
Drug: Placebo (days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (days 1-28) followed by Armodafinil 150 mg daily (days 29-56)
Trial: 22462234
Drug: Guo's Ma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guo's Ma Qian Decoction, initial dose 0.4 g, increased by 0.05 g every two days, max 1.2 g/day.
Trial: 16446336
Drug: CVI fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CVI fluorouracil (FU) 225 mg/m2 per day, 7 days per week, plus pelvic hyperfractionated radiation 55.2 to 60 Gy at 1.2 Gy bid (arm 1)
Trial: 16446336
Drug: CVI FU
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVI FU 225 mg/m2 per day Monday to Friday, 120 hours per week plus irinotecan 50 mg/m2 once weekly for 4 weeks plus pelvic radiation therapy 50.4 to 54 Gy at 1.8 Gy per day (arm 2)
Trial: 12844212
Drug: Exercise (supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise (supervised aerobic, weight‐bearing and weight‐lifting exercise, three times per week) with calcium supplementation (800 mg daily)
Trial: 8996468
Drug: Tenidap (40-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap (40-200 mg/day)
Trial: 1282537
Drug: Warfarin (traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (traditional and low-dose regimens)
Trial: 1282537
Drug: Aspirin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (three groups)
Trial: 31034598
Drug: ontuxizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ontuxizumab (8 mg/kg) plus gemcitabine and docetaxel (G/D)
Trial: 31034598
Drug: placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus gemcitabine and docetaxel (G/D)
Trial: 24947675
Drug: Oxycodone orodispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone orodispersible tablet (OOT) 20 mg
Trial: 24947675
Drug: Paracetamol orodispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol orodispersible tablet (POT) 500 mg
Trial: 23375525
Drug: 1.8 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/d of ω‐3 PUFA
Trial: 23375525
Drug: 3.6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g/d of ω‐3 PUFA
Trial: 21410828
Drug: Conjugated Estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated Estrogen (CEE) 0.625 mg/day
Trial: 21410828
Drug: Conjugated Estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated Estrogen (CEE) 0.625 mg/day plus Medroxyprogesterone Acetate (MPA) 2.5 mg/day
Trial: 19270449
Drug: 12 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg intravenous mesna administered predialysis for 1 week
Trial: 19270449
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered predialysis for 1 week
Trial: 19270449
Drug: 12 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg intravenous mesna administered predialysis for 4 weeks
Trial: 19270449
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered predialysis for 4 weeks
Trial: 15254053
Drug: Arm 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: Cisplatin 10 mg/m² daily and fluorouracil (FU) 400 mg/m² continuous infusion (CI) daily for the final 10 days of treatment
Trial: 15254053
Drug: Arm 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2: Hydroxyurea 1 g every 12 hours and FU 800 mg/m²/d CI delivered with each fraction of radiation
Trial: 15254053
Drug: Arm 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 3: Weekly paclitaxel 30 mg/m² and cisplatin 20 mg/m²
Trial: 12027068
Drug: Albuterol HFA
RxNorm normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol HFA (180 microg ex-actuator)
Trial: 12027068
Drug: Albuterol CFC
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol CFC (180 microg ex-actuator)
Trial: 7973478
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg triamcinolone hexacetonide (TA)
Trial: 7973478
Drug: 330 mg
RxNorm normalized name: urea 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 mg sodium morrhuate (SM)
Trial: 21354234
Drug: Danoprevir/r (100/100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir/r (100/100mg twice daily) plus peginterferon alfa-2a (40KD)/ribavirin
Trial: 21354234
Drug: Danoprevir/r (200/100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir/r (200/100mg once daily) plus peginterferon alfa-2a (40KD)/ribavirin
Trial: 21354234
Drug: Danoprevir/r (200/100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir/r (200/100mg twice daily) plus peginterferon alfa-2a (40KD)/ribavirin
Trial: 18506466
Drug: Liquid alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid alginate suspension (Gaviscon Advance) 10 ml four times daily after meals and at bedtime
Trial: 10768064
Drug: ticarcillin/clavulanate (3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticarcillin/clavulanate (3.1 g every 4 or 6 hours)
Trial: 9260072
Drug: Immediate, informative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate, informative monetary consequence (MI) under moderate dose of alcohol (0.62 g/kg)
Trial: 9260072
Drug: Delayed, uninformative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed, uninformative monetary consequence (M) under moderate dose of alcohol (0.62 g/kg)
Trial: 9260072
Drug: No consequence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No consequence (N) under moderate dose of alcohol (0.62 g/kg)
Trial: 7678061
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (2 x 10(6) KIU in the cardiopulmonary bypass priming solution)
Trial: 7073920
Drug: Midazolam (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.30 mg kg‐1 i.v.)
Trial: 31260526
Drug: Enzymes (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzymes (500 µg of protein/g straw DM)
Trial: 29156903
Drug: Palliative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palliative radiotherapy (single 8 Gy radiation treatment)
Trial: 26307050
Drug: Conventional intracytoplasmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intracytoplasmic sperm injection (cICSI)
Trial: 23810874
Drug: Intensified group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified group treated with RAS antagonists and beta-blockers
Trial: 21184869
Drug: Propofol plus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol plus fentanyl (0.25 mg/kg plus 50 μg intravenously)
Trial: 21184869
Drug: Midazolam plus
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam plus fentanyl (0.05 mg/kg plus 50 μg intravenously)
Trial: 20149045
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose oral contraceptives (100 microg levonorgestrel + 20 microg ethinyl estradiol)
Trial: 20149045
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral contraceptives (150 microg desogestrel + 30 microg ethinyl estradiol)
Trial: 20149045
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose oral contraceptives
Trial: 20149045
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral contraceptives
Trial: 17530986
Drug: CHO-PRO supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-PRO supplement (6.2% carbohydrate and 1.5% protein)
Trial: 17530986
Drug: CHO-PRO supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-PRO supplement
Trial: 1773716
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (INI) 1 U/kg
Trial: 28606620
Drug: Lumacaftor and
RxNorm normalized name: ivacaftor and lumacaftor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumacaftor and ivacaftor (200 mg lumacaftor and 250 mg ivacaftor every 12 hours for 24 weeks)
Trial: 25809853
Drug: Low-fat spread
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat spread with added plant sterols (3 g/d)
Trial: 22232847
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of digoxin
Trial: 22232847
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of digoxin
Trial: 10631214
Drug: Formoterol Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol Turbuhaler 24 microg metered dosage bid (delivered dosage 18 microg bid) + placebo
Trial: 10631214
Drug: Formoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 24 microg bid + bolus IV hydrocortisone, 200 mg
Trial: 10631214
Drug: Formoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 24 microg bid + bolus inhaled budesonide, 1,600 microg
Trial: 9021907
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment or digoxin for specific cases)
Trial: 1411622
Drug: Carboplatin (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (starting dose of 320 mg/m2)
Trial: 27470232
Drug: Inhaled milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled milrinone (iMil)
Trial: 22196566
Drug: 5 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 weekly 30-min massages
Trial: 22196566
Drug: 10 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weekly 30-min massages
Trial: 20143202
Drug: Humor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humor therapy group (experimental group)
Trial: 18056902
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg 3 times per day for 7 days)
Trial: 18056902
Drug: Topical Budesonide
RxNorm normalized name: budesonide Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Budesonide (200 mug in each nostril once per day for 10 days)
Trial: 18056902
Drug: No Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No Amoxicillin (placebo)
Trial: 7827843
Drug: Desmopressin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 20 micrograms intranasal at night
Trial: 30261839
Drug: Dexamethasone 0.1
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1 mg/kg intravenous bolus before anesthetic induction
Trial: 28684372
Drug: Total body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total body irradiation (TBI) 1320 cGy, cyclophosphamide 120 mg/kg, and fludarabine 75 mg/m2 (TCF)
Trial: 28684372
Drug: Nontrial chemotherapy-only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontrial chemotherapy-only regimens
Trial: 26678630
Drug: Perindopril/β-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril/β-blocker
Trial: 26678630
Drug: Placebo/β-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/β-blocker
Trial: 23076845
Drug: Oxandrolone 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.03 mg/kg per day